logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • UCB, Inc. drugs

    FiltersReset Filters
    12 results

    • bimzelx

      (bimekizumab)
      UCB, Inc.
      Usage: BIMZELX is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who qualify for systemic therapy or phototherapy.

    • briviact

      (brivaracetam)
      UCB, Inc.
      Usage: BRIVIACT is indicated for the treatment of partial-onset seizures in patients aged 1 month and older.

    • cimzia

      (certolizumab pegol)
      UCB, Inc.
      Usage: CIMZIA is indicated for treating moderate to severe Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults and eligible pediatric patients aged 2 years and older.

    • fintepla

      (fenfluramine)
      UCB, Inc.
      Usage: FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 years and older.

    • keppra

      (levetiracetam)
      UCB, Inc.
      Usage: KEPPRA is indicated for treating partial-onset seizures in patients aged 1 month and older, as adjunctive therapy for myoclonic seizures in patients 12 years and older with juvenile myoclonic epilepsy, and for primary generalized tonic-clonic seizures in patients 6 years and older with idiopathic generalized epilepsy.

    • keppra  xr - levetiracetam tablet, film coated, extended release

      (Levetiracetam)
      Ucb, Inc.

    • keppra - levetiracetam injection, solution, concentrate

      (Levetiracetam)
      Ucb, Inc.

    • nayzilam

      (midazolam)
      UCB, Inc.
      Usage: NAYZILAM is indicated for the acute treatment of intermittent, stereotypic seizure clusters or acute repetitive seizures in epilepsy patients aged 12 years and older, which are distinct from their usual seizure patterns.

    • neupro

      (rotigotine)
      UCB, Inc.
      Usage: NEUPRO is indicated for the treatment of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS).

    • rystiggo

      (ROZANOLIXIZUMAB)
      UCB, Inc.
      Usage: RYSTIGGO is indicated for treating generalized myasthenia gravis (gMG) in adult patients who test positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.